Does Cigna Cover Skyrizi for Ulcerative Colitis?

If your gastroenterologist has prescribed Skyrizi for ulcerative colitis and you have a Cigna plan, the practical question is whether Cigna will pay and what you must do to get there. The short answer is that Cigna does cover Skyrizi for ulcerative colitis when its coverage criteria are met, but approval is not automatic. Cigna manages its pharmacy benefit through Express Scripts and dispenses specialty biologics like Skyrizi through its Accredo specialty pharmacy, and it requires prior authorization before the drug is approved. Because Skyrizi (risankizumab) only earned its ulcerative colitis indication recently, the path to coverage often involves documentation of your disease severity, your prescriber's specialty, and your treatment plan. This article explains how that coverage works and what a clean approval requires.

Skyrizi for Ulcerative Colitis Is a Newer Option

Skyrizi (risankizumab-rzaa) is an interleukin-23 inhibitor that the FDA approved for moderately to severely active ulcerative colitis in adults on June 18, 2024, making it the first IL-23 specific inhibitor approved for both ulcerative colitis and Crohn's disease. Its UC approval is reflected in the current FDA prescribing information, which lists ulcerative colitis as an indication. The approval was supported by the phase 3 INSPIRE induction and COMMAND maintenance trials. In the INSPIRE study, 20.3% of patients on intravenous risankizumab achieved clinical remission at week 12 versus 6.2% on placebo. Because the indication is recent, many UC patients reaching Skyrizi have already tried other therapies, which shapes how insurers position it.

How Skyrizi Coverage Works at Cigna

Cigna runs its pharmacy benefit through Express Scripts and dispenses specialty biologics through Accredo, and it publishes coverage policies that spell out its criteria. Skyrizi for UC actually spans two of these policies because the drug uses two formulations. Treatment begins with an intravenous induction phase, then continues with subcutaneous maintenance. Cigna's intravenous coverage policy requires prior authorization for Skyrizi IV, and its subcutaneous policy states that prior authorization is recommended for the maintenance product. This split matters because both pieces of your treatment need to clear review. The exact rules, formulary tier, and out-of-pocket cost depend on your specific plan, so the published coverage policy is the starting point, not the final word for your situation.

What Cigna's Coverage Policy Typically Requires

Cigna's coverage policies set out concrete criteria for ulcerative colitis. For the intravenous induction, the policy approves three induction doses when the patient is 18 or older, the drug is used for induction, and it is prescribed by or in consultation with a gastroenterologist, with dosing of 1,200 mg by infusion at weeks 0, 4, and 8. For the subcutaneous maintenance product, initial approval similarly requires the patient to be 18 or older, to receive the three intravenous induction doses within three months, and to have a gastroenterologist involved. The policy notes that Skyrizi should generally not be used together with another biologic for an inflammatory condition. These represent Cigna's standard criteria, and your own plan documents control what applies to you.

Step Therapy and the Question of Trying Other Drugs First

Patients prescribed a newer biologic often expect a hard step-therapy requirement to fail several other drugs first. Cigna's current UC criteria for Skyrizi center on age, the induction plan, and gastroenterologist involvement rather than an explicit list of biologics you must fail. That said, step therapy can still reach you through your plan's formulary and preferred-product rules, which sit alongside the clinical policy. Cigna's policy references the AGA 2024 living guideline on moderate-to-severe ulcerative colitis, which recommends advanced therapies including risankizumab over no treatment and favors starting advanced therapy over gradual step-up with 5-aminosalicylates. Documenting your prior treatments and your disease activity strengthens the request regardless of whether a formal step is listed, and it prepares you if a preferred-product rule applies.

Reauthorization and Staying Covered

Getting an initial approval is one stage; keeping coverage is another. Cigna's subcutaneous policy approves initial UC therapy for a defined period, then reviews continuation. To approve continued Skyrizi for roughly a year, the policy requires that the patient has been established on the drug for at least six months and shows a beneficial response. That response can be demonstrated through an objective measure such as fecal calprotectin, C-reactive protein, endoscopic assessment, or a reduced corticosteroid dose, or through symptom improvement such as decreased stool frequency or reduced rectal bleeding. Tracking these markers from the start of treatment makes reauthorization smoother, because the data your gastroenterologist needs to submit will already exist. A patient who has been on therapy less than six months or is restarting is reviewed under the initial-therapy criteria instead.

How to Verify Your Own Coverage and Handle a Denial

Because plan documents always supersede the general coverage policy, confirm the specifics for your own plan before assuming an answer. Start with your plan's formulary and benefit summary to see how Skyrizi is tiered and whether it falls under the pharmacy or medical benefit, and call the member services number on your Cigna card to confirm prior-authorization requirements. If your prior authorization is denied, you have the right to appeal, and a strong appeal pairs your gastroenterologist's letter of medical necessity with documentation of disease severity and prior treatments. The same objective measures Cigna uses for reauthorization, such as fecal calprotectin and endoscopic findings consistent with the AGA guideline framework, make that case more persuasive. Coverage is achievable when the clinical record clearly supports it.